Merck & Co., Inc. vs Roundhill Russell 2000 0DTE Covered Call Strat ETF — how do they compare? Merck & Co., Inc. trades at $142.58 (market cap $351.28B), while Roundhill Russell 2000 0DTE Covered Call Strat ETF trades at $26.04 (market cap $159.33M). The key difference: Merck & Co., Inc. is far larger — about 2204.7× Roundhill Russell 2000 0DTE Covered Call Strat ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Roundhill Russell 2000 0DTE Covered Call Strat ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Roundhill Russell 2000 0DTE Covered Call Strat ETF for 53 Days on average.
| MRK | RDTE | |
|---|---|---|
Market Cap | $351.28B | $159.33M |
Volume | 7,969,665 | 248,058 |
Sector | Health | Income / Options Overlay |
52-Week High | $156.43 | $33.66 |
52-Week Low | $82.49 | $25.96 |
Typical Hold Time | 98 Days | 53 Days |
Enterprise Value | $398.04B | — |
Dividend Yield | 2.39% | — |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →RDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the Russell 2000 Index. The fund primarily holds a portfolio of short-term U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the Russell 2000. This highly tactical strategy aims to maximize premium capture by exploiting the high time decay of options that are expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on RDTE →